(vianews) - shares of gensight biologics (cac 40: sight.pa) fell by a staggering 18.1% in 5 sessions from €0.93 to €0.76 at 17:53 est on monday, following the last session's downward trend. cac 40 is rising 0.29% to €7,184.04, after five consecutive sessions in a row of losses.
about gensight biologics
gensight biologics s.a., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. the company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. its lead product candidates include lumevoq (gs010), a recombinant aav2-based gene therapy, which is in phase iii clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated nd4 gene; and gs030, which is in phase i/ii clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. the company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. the company was incorporated in 2012 and is headquartered in paris, france.
earnings per share
as for profitability, gensight biologics has a trailing twelve months eps of €-0.57.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, gensight biologics's stock is considered to be overbought (>=80).
volatility
gensight biologics's last week, last month's, and last quarter's current intraday variation average was a negative 5.35%, a positive 0.18%, and a positive 5.40%.
gensight biologics's highest amplitude of average volatility was 6.16% (last week), 3.99% (last month), and 5.40% (last quarter).
more news about gensight biologics (sight.pa).